D
Karuna Therapeutics, Inc. KRTX
$196.53 $5.322.78%
Recommendation
Sell
Prev Close
$196.53
Volume
227,697
Avg Vol (90D)
247,146
Market Cap
$7.41B
Dividend & Yield
--
52-Week Range
$158.38 - $245.00
P/E (TTM)
--
EPS (TTM)
-$10.93
My Lists My Alerts
Report
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Karuna Therapeutics (KRTX) and Argenx Se (ARGX)
12/1/2023 - TipRanks Financial Blog
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Receives Average Recommendation of "Moderate Buy" from Brokerages
12/1/2023 - Zolmax
3,428 Shares in Karuna Therapeutics, Inc. (NASDAQ:KRTX) Purchased by B. Metzler seel. Sohn & Co. AG
11/30/2023 - Ticker Report
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
11/29/2023 - Business Wire
Optimistic Buy Rating for Karuna Therapeutics Amidst FDA Acceptance and Promising Market Prospects
11/29/2023 - TipRanks Financial Blog
FDA accepts Karuna Therapeutics schizophrenia drug for review
11/29/2023 - SeekingAlpha.com: All News
FDA accepts Karuna Therapeutics schizophrenia drug for review
11/29/2023 - Seeking Alpha - Healthcare
Karuna Therapeutics announces FDA accepted NDA for KarXT
11/29/2023 - The Fly
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
11/29/2023 - Business Wire
MYDA Advisors LLC Sells 1,000 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)
11/27/2023 - Ticker Report
Capital International Sarl Makes New Investment in Karuna Therapeutics, Inc. (NASDAQ:KRTX)
11/24/2023 - Ticker Report
Atika Capital Management LLC Has $14.10 Million Stock Position in Karuna Therapeutics, Inc. (NASDAQ:KRTX)
11/23/2023 - Ticker Report
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Karuna Therapeutics (KRTX) and Theseus Pharmaceuticals (THRX)
11/23/2023 - TipRanks Financial Blog
The Latest Analyst Ratings for Karuna Therapeutics
11/20/2023 - Benzinga
Positive Phase 1b Trial Results Bolster Buy Rating for Karuna Therapeutics: Potential for Rapid Market Adoption of KarXT
11/20/2023 - TipRanks Financial Blog
Karuna Therapeutics' KarXT: A Promising Drug with Negligible Cardiovascular Risk A Buy Recommendation
11/20/2023 - TipRanks Financial Blog
Karuna Therapeutics Stock Receives Buy Rating Following Successful Phase 1b ABPM Study Results of KarXT
11/20/2023 - TipRanks Financial Blog
Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Karuna Therapeutics (KRTX) and Masimo (MASI)
11/19/2023 - TipRanks Financial Blog
Karuna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia Patients
11/17/2023 - Benzinga
PureTech Health entity Karuna Therapeutics announces results from KarXT trial
11/17/2023 - The Fly
Karuna Therapeutics (KRTX, $168.09) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 16, 2023
11/17/2023 - Tickeron - Stocks
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
11/17/2023 - Business Wire
Analysts Are Bullish on These Healthcare Stocks: Notable Labs (NTBL), Karuna Therapeutics (KRTX)
11/17/2023 - TipRanks Financial Blog
Analyst Endorses Karuna Therapeutics' KarXT Following Positive Safety Trial Results and Anticipates High Market Potential
11/17/2023 - TipRanks Financial Blog
Karuna Therapeutics announces 'positive' results from Phase 1b KarXT trial
11/16/2023 - The Fly
Income Statement
Total Revenue (TTM)
$5.93M
EBITDA (TTM)
-$448.08M
EBIT (TTM)
-$449.64M
Net Income (TTM)
-$396.07M
Balance Sheet
Total Assets (Q)
$1.39B
Total Debt (Q)
$15.61M
Total Liabilities (Q)
$62.78M
Book Value Per Share (Q)
$35.06
Cash Flow
Cash from Operations (TTM)
-$353.52M
Cash from Investing (TTM)
-$559.38M
Cash from Financing (TTM)
$468.89M
Net Change in Cash (TTM)
-$444.00M
Filings
Filing Date
Thursday, November 2, 2023
Period Date
Saturday, September 30, 2023
Next Filing
Week of Feb 19 and 23 (est)
Price History
Loading...
Beta
1.16
7-Day Total Return
1.65%
30-Day Total Return
14.66%
60-Day Total Return
3.79%
90-Day Total Return
-3.64%
Year to Date Total Return
-1.02%
1-Year Total Return
-19.26%
2-Year Total Return
50.99%
3-Year Total Return
97.65%
5-Year Total Return
--
52-week Low
Oct 03, 2023 - $158.38
52-week High
Jun 14, 2023 - $245.00
Valuation
Market Cap
$7.41B - Mid Cap
Enterprise Value
$6.09B
Price/Sales (TTM)
1,249.40
Price/Book (Q)
5.61
Dividends and Shares
Shares Outstanding
37.69M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.karunatx.com
Phone Number
857 449 2244
Address
99 High Street
Boston, MA 02110
Country
United States
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead... more
NASDAQ 12/01/2023 4:00PM Eastern Quotes delayed
Weiss Ratings